MARKET

CYAD

CYAD

Celyad Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.74
+0.43
+8.10%
Pre Market: 5.73 -0.01 -0.17% 04:12 05/14 EDT
OPEN
5.90
PREV CLOSE
5.31
HIGH
6.00
LOW
5.36
VOLUME
2.65K
TURNOVER
--
52 WEEK HIGH
13.01
52 WEEK LOW
5.25
MARKET CAP
80.03M
P/E (TTM)
-3.8086
1D
5D
1M
3M
1Y
5Y
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) jumped 38.7% to $4.0901 after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc.
Benzinga · 16h ago
AMC, OCGN, SONO and HRTX among premarket gainers
Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT)
Seekingalpha · 19h ago
Celyad shares surge ahead of upcoming multiple myeloma study poster presentation
Celyad Oncology (CYAD) shares rise nearly 20% during premarket trading after the company's abstract highlighting initial data from an early-stage trial of multiple myeloma treatment CYAD-211 was accepted for e-poster presentation at the upcoming European
Seekingalpha · 20h ago
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 20h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 20h ago
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Fuel Tech, Inc. (NASDAQ: FTEK) shares rose 26.3% to $2.45 in pre-market trading after the company reported upbeat results for its first quarter on Wednesday.
Benzinga · 21h ago
Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy
Benzinga · 21h ago
Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
No Grade ≥ 3 treatment-related adverse events nor evidence of Graft-versus-Host disease reported from the completed first dose-level (DL1) cohort of Phase 1 dose-escalation IMMUNICY-1 trial evaluating the shRNA-based anti-BCMA CAR T candidate, CYAD-211, fo...
GlobeNewswire · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYAD. Analyze the recent business situations of Celyad Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYAD stock price target is 18.38 with a high estimate of 19.87 and a low estimate of 16.89.
EPS
Institutional Holdings
Institutions: 12
Institutional Holdings: 790.40K
% Owned: 5.67%
Shares Outstanding: 13.94M
TypeInstitutionsShares
Increased
1
1.39K
New
0
0
Decreased
1
40.89K
Sold Out
1
53
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Co-Founder/Director
Michel Lussier
Chief Executive Officer/Executive Director/Executive Board
Christian Homsy
Chief Financial Officer/Executive Board/Primary Contact
Patrick Jeanmart
Chief Operating Officer
Gaetane Metz
Vice President
Richard Mountfield
Vice President - Research & Development/Executive Board
Peter De Waele
Vice President - Business Development
Georges Rawadi
Other
Seron Aymeric
Other
Philippe Dechamps
Other
Roland Gordon-Beresford
Non-Executive Director
Serge Goblet
Non-Executive Director
Hanspeter Spek
Non-Executive Director
William Wijns
Independent Director
Chris Buyse
Independent Director
Rudy Dekeyser
No Data
  • All
  • Financials
  • Insiders
No Data
About CYAD
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Webull offers kinds of Celyad Oncology SA stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYAD stock methods without spending real money on the virtual paper trading platform.